Migraine in women

CONTINUUM Lifelong Learning in Neurology

Volumn 18, Issue 4, 2012, Pages 835-852

  Brandes, Jan Lewis ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM; CALCIUM CHANNEL BLOCKING AGENT; CYCLOOXYGENASE 2 INHIBITOR; DIHYDROERGOTAMINE; ERGOTAMINE; ESTRADIOL; ESTROGEN; FOLIC ACID; FROVATRIPTAN; GABAPENTIN; MAGNESIUM; MELATONIN; NAPROXEN; NARATRIPTAN; NONSTEROID ANTIINFLAMMATORY AGENT; NORTRIPTYLINE; ORAL CONTRACEPTIVE AGENT; SEROTONIN; SUMATRIPTAN; TOPIRAMATE; TRICYCLIC ANTIDEPRESSANT AGENT; VITAMIN D; ZOLMITRIPTAN;

ANALGESIA; BODY WEIGHT; BONE DISEASE; COGNITION; COMORBIDITY; DEPRESSION; DIETARY INTAKE; DISEASE DURATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EFFICACY; ESTROGEN BLOOD LEVEL; ESTROGEN THERAPY; EXERCISE; FUNCTIONAL DISEASE; HEADACHE; HEALTH EDUCATION; HUMAN; LOW DRUG DOSE; MENOPAUSE; MENSTRUAL CYCLE; MENSTRUAL MIGRAINE; MENSTRUATION; MIGRAINE; NAUSEA AND VOMITING; REASSURANCE; RECOMMENDED DRUG DOSE; REVIEW; RISK FACTOR; SLEEP; SMOKING CESSATION; STROKE; TREATMENT RESPONSE; WEIGHT CONTROL;

ADULT; CONTRACEPTIVES, ORAL; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; MENSTRUAL CYCLE; MIDDLE AGED; MIGRAINE DISORDERS; PREGNANCY; WOMEN'S HEALTH; YOUNG ADULT;

EID: 84864867820     PISSN: 10802371     EISSN: 15386899     Source Type: Journal    
DOI: 10.1212/01.CON.0000418646.70149.71     Document Type: Review

References (58)

1. Welch KM, Darnley D, Simkins RT. The role of estrogen in migraine a review and hypothesis. Cephalalgia 1984;4(4) 227-236. (Pubitemid 15127054)
2. Lipton RB, Stewart WF, Diamond S, et al. Prevalence and burden of migraine in the United States data from the American Migraine Study II. Headache 2001;41(7) 646-657. (Pubitemid 32777747)
3. Brandes J. The influence of estrogen on migraine a systematic review. JAMA 2006;295(15) 1824-1830.
4. Granella F, Sances G, Allais G, et al. Characteristics of menstrual and nonmenstrual attacks in women with menstrually related migraine referred to headache centers. Cephalalgia 2004;24(9) 707-716. (Pubitemid 39209074)
5. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders 2nd edition. Cephalalgia 2004; 24(suppl 1) 9-160.
6. Somerville BW. The role of estradiol withdrawal in the etiology of menstrual migraine. Neurology 1972;22(4) 355-365.
7. Welch KMA, Brandes JL, Berman N. Mismatch in how estrogen modulates molecular and neuronal function may explain menstrual migraine. Neurol Sci 2006;27(suppl 2) S190YS192. (Pubitemid 44390140)
8. Martin V, Behbehani M. Ovarian hormones and migraine headache understanding mechanisms and pathogenesisVpart I. Headache 2006;46(1) 3-23.
9. Hershey A, Horn P, Kabbouche M, et al. Genomic expression patterns in menstrual-related migraine in adolescents. Headache 2012;52(1) 68-79.
10. Loder E, Rizzoli P, Golub J. Hormonal management of migraine associated with menses and the menopause a clinical review. Headache 2007;47(2) 329-340.
11. MacGregor EA. Menstrual migraine therapeutic approaches. Ther Adv Neurol Disord 2009;2(5) 327-336.
12. Nett R, Landy S, Shackelford S, et al. Pain-free efficacy after treatment with sumatriptan in the mild pain phase of menstrually associated migraine. Obstet Gynecol 2003;102(4) 835-842. (Pubitemid 37206421)
13. Mannix LK, Loder E, Nett R, et al. Rizatriptan for the acute treatment of ICHD-II proposed menstrual migraine two prospective, randomized, placebo-controlled, double-blind studies. Cephalalgia 2007;27(5) 414-421. (Pubitemid 46632603)
14. Tuchman M, Hee A, Emeribe U, Silberstein S. Efficacy and tolerability of zolmitriptan oral tablet in the acute treatment of menstrual migraine. CNS Drugs 2006;20(12) 1019-1026. (Pubitemid 44912709)
15. Newman L, Mannix LK, Landy S, et al. Naratriptan as short-term prophylaxis of menstrually associated migraine a randomized, double-blind, placebo-controlled study. Headache 2001;41(3) 248-256. (Pubitemid 32242609)
16. Brandes JL, Poole AC, Kallela M, et al. Short-term frovatriptan for the prevention of difficult-to-treat menstrual migraine attacks. Cephalalgia 2009;29(11) 1133-1148.
17. Sances G, Martignoni E, Fioroni L, et al. Naproxen sodium in menstrual migraine prophylaxis a double-blind placebo controlled study. Headache 1990;30(11) 705-709.
18. Brandes J. Headache related to pregnancy management of migraine and migraine headache in pregnancy. Curr Treat Options Neurol 2008;10(1) 12-19. (Pubitemid 351176051)
19. Brandes JL. Managing migraine headache. Headache Q 2000;(suppl 1) 25-28.
20. Boyle CA. Management of menstrual migraine. Neurology 1999;53(4 suppl 1) S14YS18. (Pubitemid 29448336)
21. US Department of Health and Human Services Office of Women's Health. Preconception health. www.womenshealth. gov/pregnancy/before-you-get-pregnant/ preconception-health.cfm. Updated September 27, 2010. Accessed June 18, 2012.
22. De Lignieres B, Vincens M, Mauvais-Jarvis P, et al. Prevention of menstrual migraine by percutaneous oestradiol. Br Med J (Clin Res Ed) 1986;293(6561) 1540. (Pubitemid 17016357)
23. Dennerstein L, Morse C, Burrows G, Oats J, et al. Menstrual migraine a double-blind trial of percutaneous estradiol. Gynecol Endocrinol 1988;2(2) 113-120.
24. Smits MG, van der Meer YG, Pfeil JP, et al. Perimenstrual migraine effect of Estraderm TTS and the value of contingent negative variation and exteroceptive temporalis muscle suppression test. Headache 1993;34(2) 103-106. (Pubitemid 24081718)
25. Pradalier A, Vincent D, Beaulieu PH, et al. Correlation between estradiol plasma level and therapeutic effect on menstrual migraine. Proc 10th Migraine Trust Symp 1994;129-132.
26. Loder EW, Buse DC, Golub JR. Headache as a side effect of combination estrogen-progestin oral contraceptives a systematic review. Am J Obstet Gynecol 2005;193(3 pt 1) 636-649. (Pubitemid 41261456)
27. Sulak PJ, Kuehl TJ, Oritz M, Shull BL. Acceptance of altering the standard 21-day/7-day oral contraceptive regimen to delay menses and reduce hormone withdrawal symptoms. Am J Obstet Gynecol 2002;186(6) 1142-1149. (Pubitemid 34665050)
28. ACOG Committee on Practice Bulletins Gynecology. ACOG practice bulletin. No. 73 use of hormonal contraception in women with coexisting medical conditions. Obstet Gynecol 2006;107(6) 1453-1472.
29. Allais G, Gabellari IC, De Lorenzo C, et al. Oral contraceptives in migraine therapy. Neurol Sci 2011;32(suppl 1) S135YS139.
30. Nappi EW, Sances G, Allais G, et al. Effects of an estrogen-free, desogestrel-containing oral contraceptive in women with migraine with aura a prospective diary-based pilot study. Contraception 2011;83(3) 223-228.
31. Sances G, Granella F, Nappi R, et al. Course of migraine during pregnancy and postpartum a prospective study. Cephalalgia 2003;23(3) 197-205. (Pubitemid 36461389)
32. Kvisvik EV, Stovner LJ, Helde G, et al. Headache and migraine during pregnancy and puerperium the MIGRA-study. J Headache Pain 2011;12(4) 443-451.
33. University of Washington. FDA pregnancy category. depts.washington.edu/ druginfo/Formulary/Pregnancy.pdf. Accessed June 14, 2012.
34. The sumatriptan/naratriptan/Treximet pregnancy registry interim report 1 January 1996 through 30 April 2011. pregnancyregistry.gsk.com/documents/ SumNarTrex-InterimReport-2011.pdf. Issued August 2011. Accessed April 6, 2012.
35. Lucas S. Medication use in the treatment of migraine during pregnancy and lactation. Curr Pain Headache Rep 2009;13(5) 392-398.
36. US Food and Drug Administration. FDA drug safety communication risk of oral clefts in children born to mothers taking Topamax (topiramate). www.fda.gov/Drugs/DrugSafety/ucm245085.htm. Updated March 7, 2011. Accessed May 4, 2012.
37. American Academy of Pediatrics Committee on Drugs. Transfer of drugs and other chemicals into human milk. Pediatrics 2001;108(3) 776-789.
38. Briggs GG, Freeman RK, Yaffe SJ. Drugs in pregnancy and lactation, 6th ed. Philadelphia, PA Lippincott Williams & Wilkins, 2002.
39. World Health Organization Scientific Group. Report of WHO Scientific Group research on the menopause in the 1990's. Geneva, Switzerland World Health Organization, 1996.
40. Greendale GA, Lee NP, Arriola ER. The menopause. Lancet 1999;353(9152) 571-580. (Pubitemid 29078438)
41. Neri I, Granella F, Nappi R, et al. Characteristics of headache at menopause a clinico-epidemiologic study. Maturitas 1993;17(1) 31-37.
42. Santoro N, Brown JR, Adel T, Skurnick JH. Characterization of reproductive hormonal dynamics in the perimenopause. J Clin Endocrinol Metab 1996;81(4) 1495-1501. (Pubitemid 26118582)
43. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288(3) 321-333. (Pubitemid 34761611)
44. Facchinetti F, Nappi RE, Tirelli A, et al. Hormone supplementation differently affects migraine in postmenopausal women. Headache 2002;42(9) 924-929. (Pubitemid 35285386)
45. Martin V, Behbehani M. Ovarian hormones and migraine headache understanding mechanisms and pathogenesisVpart 2. Headache 2006;46(3) 365-386.
46. Martin V, Wernke S, Mandell K, et al. Medical oophorectomy with and without estrogen add-back therapy in the prevention of migraine headache. Headache 2003;43(4) 309-321. (Pubitemid 36417760)
47. Burke BE, Olson RD, Cusack BJ. Randomized, controlled trial of phytoestrogen in the prophylactic treatment of menstrual migraine. Biomed Pharmacother 2002; 56(6) 283-288. (Pubitemid 35245311)
48. US Preventive Services Task Force. Hormone therapy for the prevention of chronic conditions in postmenopausal women recommendations from the US Preventive Services Task Force. Ann Intern Med 2005; 142(10) 855-860.
49. Spector JT, Kahn SR, Jones MR, et al. Migraine headache and ischemic stroke risk an updated meta-analysis. Am J Med 2010;123(7) 612-624.
50. Collaborative Group for the Study of Stroke in Young Women. Oral contraceptives and stroke in young women associated risk factors. JAMA 1975;231(7) 718-722.
51. Bousser MG. International Headache Society (IHS) Task Force on oral contraceptives (OCs) and hormone replacement therapy (HRT) used in migraine sufferers. Cephalalgia 2000;20(3) 147; discussion 145-146.
52. Davis PH. Use of oral contraceptives and postmenopausal hormone replacement evidence on risk of stroke. Curr Treat Options Neurol 2008;10(6) 468-474.
53. Sherwin BB. The critical period hypothesis can it explain discrepancies in the oestrogen-cognition literature? J Neuroendocrinol 2007;19(2) 77-81. (Pubitemid 46043829)
54. Zhang Q-G, Raz L, Wang R, et al. Estrogen attenuates ischemic oxidative damage via an estrogen receptor alphaYmediated inhibition of NADPH oxidase activation. J Neurosci 2009;29(44) 13823-13836.
55. Renoux C, Dell'aniello S, Garbe E, Suissa S. Transdermal and oral hormone replacement therapy and the risk of a stroke a nested case-control study. BMJ 2010;340 c2519.
56. Shuster LT, Faubion SS, Sood R, Casey PM. Hormonal manipulation strategies in the management of menstrual migraine and other hormonally related headaches. Curr Neurol Neurosci Rep 2011;11(2) 131-138.
57. Breslau N, Lipton RB, Stewart WF, et al. Comorbidity of migraine and depression investigating potential etiology and prognosis. Neurology 2003;60(8) 1308-1312. (Pubitemid 36460987)
58. Tietjen GE, Brandes JL, Digre KB, et al. History of childhood maltreatment is associated with comorbid depression in women with migraine. Neurology 2007; 69(10) 959-968. (Pubitemid 47366048)